Tumor Targeted Corroles for Detection and Intervention
用于检测和干预的肿瘤靶向作用
基本信息
- 批准号:8599443
- 负责人:
- 金额:$ 32.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-02-05 至 2014-12-31
- 项目状态:已结题
- 来源:
- 关键词:AdenovirusesAffinityAlkanesulfonatesBindingBiodistributionBiological ModelsCapsidCarrier ProteinsCell CommunicationCell DeathCell NucleusCell Surface ReceptorsCellsCollaborationsComplexCytoplasmCytoskeletonCytosolDetectionDevelopmentDoseDoxorubicinDrug KineticsERBB2 geneEpidermal Growth Factor ReceptorFluorescenceGalliumGliomaGray unit of radiation doseHeregulinHumanImageImageryImmuneImmune SeraIn VitroInterventionInvestigationLeadLigandsMacrocyclic CompoundsMalignant NeoplasmsMediatingMembraneMembrane ProteinsMetabolicMethodologyMitochondriaMitoticModelingModificationMultimodal ImagingMutationNational Cancer InstituteOvarianPenetrationPilot ProjectsPost-Translational Protein ProcessingPropertyProteinsPublic HealthPublishingRegimenResearchResearch Project GrantsSafetySerumSystemTechnologyTertiary Protein StructureTestingTherapeuticToxic effectTreatment EfficacyVariantWateralternative treatmentbasebiological systemscancer cellcell killingcell typechemotherapycorrolecytotoxicitydirected evolutiondosagedrug metabolismimprovedin vivokillingsmalignant breast neoplasmneoplastic cellnew therapeutic targetnoveloutcome forecastoverexpressionpenton basepreventprostate cancer cellreceptorreceptor mediated endocytosisscreeningtargeted deliverytumortumor growthuptake
项目摘要
ABSTRACT
This proposal will test the hypothesis that noncovalent corrole assemblies simultaneously mediate both
tumor targeted detection and intervention in a single self-assembled complex.
Sulfonated corroles are water soluble, macrocyclic compounds that may be metallated and can emit an
intense fluorescence. We have found that corroles spontaneously assemble with carrier proteins, which are
required to facilitate cel entry, and once entering cels, must be released into the cytoplasm to elicit
cytotoxicity while remaining excluded from the nucleus, thus implicating cytosolic factors as the targets of
corrole-mediated toxicity. Our targeted cell penetration protein, HerPBK10, enables corrole uptake into
HER2+ cancer cells in vitro and in vivo. HerPBK10 is comprised of a cell-targeting and internalizing ligand
derived from the heregulin protein, and membrane penetration domain derived from the adenovirus (Ad)
capsid penton base. Corrole fluorescence enables visualization of tumor cell targeting in vitro and in vivo,
and tumor targeting in vivo results in tumor growth intervention at nearly 300x less dosage in
comparison to direct intratumoral delivery of the chemotherapy agent, doxorubicin.
HER2+ cancer has served as a model system for testing new targeted therapeutics in our lab. As the
overexpression of the HER2 (or ErbB2) subunit enhances receptor affinity, the HER2+ cell type is an ideal
model for testing ligand-directed therapies. More importantly, as HER2 overexpression in breast cancer
correlates with aggressive chemoresistant tumors and predicts a poor prognosis, alternative treatments to
standard regimens may prove more effective on this subset of breast cancers that, while not comprising a
majority of cases, are among the most deadly of breast cancers. Nevertheless, we have identified additional
potential targets of our heregulin-directed therapeutics, including ovarian, glioma, and prostate cancer cells
that express high levels of different HER subunits. Thus, the HER-targeted system presented here may have
a broader application to several different tumor types in addition to HER2+ breast cancer.
This proposal combines the expertise of multiple collaborators to further develop corrole assemblies into
image-able tumor targeting agents. We will assess target cell and immune interactions with the carrier
protein to direct efforts in introducing modifications that may enhance therapeutic efficacy and safety. One
exciting direction we will explore is to apply directed evolution to select carrier protein domains to improve
target cell interactions and immune evasion. We will test these modifications for corrole delivery in vitro
and in vivo, and utilize the unique photoemission properties of corroles to detect in vivo tumor targeting.
摘要
这一提议将检验非共价Corole组件同时调节两者的假设
在单个自组装复合体中进行肿瘤靶向检测和干预。
磺化腐蚀剂是一种可溶于水的大环化合物,可被金属化,并可释放出
强烈的荧光。我们已经发现,腐蚀剂会自发地与载体蛋白组装,载体蛋白是
需要促进细胞进入,一旦进入细胞,必须释放到细胞质中以诱导
细胞毒性,但仍被排除在核外,因此暗示胞液因子是靶点
科罗尔介导的毒性。我们的靶向细胞穿透蛋白HerPBK10使Corole能够摄取到
HER2+癌细胞的体外和体内实验。HerPBK10由细胞靶向和内化配体组成
来源于HERG蛋白,以及来源于腺病毒(Ad)的膜穿透结构域
卡西德·潘顿基地。Corole荧光使体外和体内肿瘤细胞靶向的可视化成为可能,
体内肿瘤靶向导致以近300倍的剂量进行肿瘤生长干预
与直接瘤内注射化疗药物阿霉素进行比较。
HER2+癌症已经成为我们实验室测试新的靶向治疗的模型系统。作为
HER2(或ErbB2)亚单位的过表达增强了受体的亲和力,HER2+细胞类型是理想的
测试配基导向疗法的模型。更重要的是,随着HER2在乳腺癌中的过度表达
与侵袭性的化疗耐药肿瘤相关,并预测预后不良,替代治疗
标准方案可能被证明对这类乳腺癌更有效,虽然不包括
大多数病例都是最致命的乳腺癌之一。尽管如此,我们已经确定了其他
HERG导向疗法的潜在靶点,包括卵巢、胶质瘤和前列腺癌细胞
高水平表达不同的HER亚基。因此,此处提供的针对HER的系统可能具有
除了HER2+乳腺癌外,更广泛的应用于几种不同的肿瘤类型。
此建议结合了多个合作者的专业知识,以进一步开发Corole程序集
可成像的肿瘤靶向剂。我们将评估靶细胞和免疫与携带者的相互作用
在引入修饰方面引导努力的蛋白质,可提高治疗效果和安全性。一
我们将探索的激动人心的方向是应用定向进化来选择载体蛋白结构域进行改进
靶细胞相互作用和免疫逃避。我们将在体外测试这些改良剂对科罗尔的释放。
和体内,并利用腐蚀剂独特的光电子发射特性来检测体内肿瘤靶向。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LALI K MEDINA-KAUWE其他文献
LALI K MEDINA-KAUWE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LALI K MEDINA-KAUWE', 18)}}的其他基金
Targeting inhibitor-resistant breast tumors with HER3-homing nano-capsids
使用 HER3 归巢纳米衣壳靶向抑制剂耐药性乳腺肿瘤
- 批准号:
10367490 - 财政年份:2022
- 资助金额:
$ 32.21万 - 项目类别:
Targeting inhibitor-resistant breast tumors with HER3-homing nano-capsids
使用 HER3 归巢纳米衣壳靶向抑制剂耐药性乳腺肿瘤
- 批准号:
10619565 - 财政年份:2022
- 资助金额:
$ 32.21万 - 项目类别:
Nucleocapsid bioparticles eliciting multi-pronged attack on tumor metastases
核衣壳生物颗粒引发对肿瘤转移的多管齐下攻击
- 批准号:
10610443 - 财政年份:2022
- 资助金额:
$ 32.21万 - 项目类别:
Tumor Targeted Corroles for Detection and Intervention
用于检测和干预的肿瘤靶向作用
- 批准号:
8403815 - 财政年份:2010
- 资助金额:
$ 32.21万 - 项目类别:
Tumor Targeted Corroles for Detection and Intervention
用于检测和干预的肿瘤靶向作用
- 批准号:
7889775 - 财政年份:2010
- 资助金额:
$ 32.21万 - 项目类别:
Tumor Targeted Corroles for Detection and Intervention
用于检测和干预的肿瘤靶向作用
- 批准号:
8021832 - 财政年份:2010
- 资助金额:
$ 32.21万 - 项目类别:
Tumor Targeted Corroles for Detection and Intervention
用于检测和干预的肿瘤靶向作用
- 批准号:
8206856 - 财政年份:2010
- 资助金额:
$ 32.21万 - 项目类别:
Corrole nanobiologics for targeting resistant and metastatic tumors
Corrole 纳米生物制剂用于靶向耐药性和转移性肿瘤
- 批准号:
9769633 - 财政年份:2009
- 资助金额:
$ 32.21万 - 项目类别:
Corrole nanobiologics for targeting resistant and metastatic tumors
Corrole 纳米生物制剂用于靶向耐药性和转移性肿瘤
- 批准号:
10241418 - 财政年份:2009
- 资助金额:
$ 32.21万 - 项目类别:
Corrole nanobiologics for targeting resistant and metastatic tumors
Corrole 纳米生物制剂用于靶向耐药性和转移性肿瘤
- 批准号:
10017161 - 财政年份:2009
- 资助金额:
$ 32.21万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 32.21万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 32.21万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 32.21万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 32.21万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 32.21万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 32.21万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 32.21万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 32.21万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 32.21万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 32.21万 - 项目类别:
Continuing Grant